70 results
DFAN14A
FBRX
Forte Biosciences Inc
14 Sep 23
Additional proxy materials by non-management
4:00pm
of shareholders […]”
“We agree with the Dissident’s assessment that the Company’s share issuances in mid-2022 and in July 2023 do not appear to have
DEFA14A
FBRX
Forte Biosciences Inc
1 Sep 23
Additional proxy soliciting materials
5:25pm
liquidation Reviewed in-licensing options Evaluation internal candidate, FB-102 May 2022 after thorough assessment of options announced plan to advance FB-102
DEFC14A
u265blfx2maxah8a6n
24 Aug 23
Proxy in contested solicitation
6:15am
PREC14A
8piojnocu0ks7h63ipn
2 Aug 23
Preliminary proxy with contested solicitation
5:28pm
8-K
EX-10.1
dk0jpfr7v2x u8ovwho
1 Aug 23
Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102
4:06pm
424B5
kovnw1c yhm
12 Aug 22
Prospectus supplement for primary offering
4:46pm
8-K
EX-10.1
b97rs7 ibd
31 Mar 22
Entry into a Material Definitive Agreement
8:57pm
424B5
p1g6di6j8
31 Mar 22
Prospectus supplement for primary offering
8:55pm